ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	21,837	$	46,156
Restricted cash	—		1,501
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	21,837	$	47,657

Cash, Cash Equivalents and Restricted Cash, Reconciliation

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	21,837	$	46,156
Restricted cash	—		1,501
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	21,837	$	47,657

Property and Equipment

Property and equipment consisted of the following:

(in thousands, except useful lives)	Estimated Useful Lives				December 31, 2022		December 31, 2021
Lab equipment			5	Years	0		530
Manufacturing equipment			5	Years	0		138
Computer and office equipment	3	to	5	Years	510		841
Software			3	Years	82		94
Total					592		1,603
Less: accumulated depreciation					(570)		(1,591)
Property and equipment, net					$	22	$	12

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following:

	December 31, 2022		December 31, 2021
Accrued payroll	264		$	320
Accrued patient treatment costs	675		2,086
Accrued clinical research costs	841		479
Accrued manufacturing costs	434		328
Accrued professional services	207		305
Accrued other	56		331
Total accrued expenses and other current liabilities	$	2,477	$	3,849

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following outstanding shares of common stock equivalents were excluded from the computations of diluted earnings per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.

	December 31, 2022	December 31, 2021
Anti-dilutive common stock equivalents:	Number of Shares
Redeemable convertible series 1 preferred stock	4,520,000	4,520,000
Warrants to purchase common stock	5,750,000	5,750,000
Options to purchase common stock	3,678,176	2,140,618
Unvested shares of restricted stock units	223,133	137,504
Total anti-dilutive common stock equivalents	14,171,309	12,548,122